About AGT103-T

AGT™ developed AGT103-T, a patented lentivirus designed to give CD4 T cells the ability to survive attack by HIV.

• How does it work?
• When will your product be available?
• What is AGT103-T?
• Will AGT103-T work?
• How much will AGT103-T cost?
• If the study product does not make modifications to CXCR4 for safety reasons, then will this product not work on someone whose profile comes back as CXCR4-type HIV?
• Does AGT103-T remove HIV from CD4 cells’ DNA so transplanted cells don’t virally replicate when ART ends, leading to the cells’ death?
• If the product inhibits release of virus from the cells by destabilizing virus RNA so the cells cannot produce the virus, why introduce genes to protect the outer wall of the cell at the CCR5 site?
• Was there any actual ex-vivo evidence AGT™ or NIH/Dr. Chun’s ex-vivo lab work that suggested latently infected cells were destroyed or viral release from latently infected inhibitors?
• If AGT103-T can inhibit replication in latently infected cells, are you hoping for a functional cure but not expecting a sterilizing cure that eliminates all infected cells?